1. Home
  2. MIRM vs OZKAP Comparison

MIRM vs OZKAP Comparison

Compare MIRM & OZKAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$65.07

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo Bank OZK 4.625% Series A Non-Cumulative Perpetual Preferred Stock

OZKAP

Bank OZK 4.625% Series A Non-Cumulative Perpetual Preferred Stock

HOLD

Current Price

$16.36

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
OZKAP
Founded
2018
N/A
Country
United States
United States
Employees
355
3246
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
N/A
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
OZKAP
Price
$65.07
$16.36
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$87.55
N/A
AVG Volume (30 Days)
560.0K
N/A
Earning Date
11-04-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$471,794,000.00
N/A
Revenue This Year
$53.78
N/A
Revenue Next Year
$19.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.66
N/A
52 Week Low
$36.88
N/A
52 Week High
$78.55
N/A

Technical Indicators

Market Signals
Indicator
MIRM
OZKAP
Relative Strength Index (RSI) 36.47 38.12
Support Level $63.66 $16.28
Resistance Level $66.77 $16.65
Average True Range (ATR) 2.99 0.23
MACD -0.66 0.02
Stochastic Oscillator 13.68 16.06

Price Performance

Historical Comparison
MIRM
OZKAP

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About OZKAP Bank OZK 4.625% Series A Non-Cumulative Perpetual Preferred Stock

Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides a range of banking services which include deposit services such as checking, savings, money market, time deposit, and individual retirement accounts to loan services like real estate, consumer, commercial, and industrial loans. Apart from providing traditional banking products and services it also provides treasury management, trust and wealth management, financial planning, online banking, and other related services.

Share on Social Networks: